Pediatrix Medical Group (NYSE:MD) Now Covered by Macquarie

Equities research analysts at Macquarie initiated coverage on shares of Pediatrix Medical Group (NYSE:MD - Get Free Report) in a research note issued on Monday, Marketbeat reports. The firm set an "outperform" rating and a $18.00 price target on the stock. Macquarie's price objective indicates a potential upside of 24.48% from the company's current price.

Other equities analysts have also recently issued research reports about the company. Mizuho boosted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Tuesday, November 19th. Truist Financial lifted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft increased their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Jefferies Financial Group boosted their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Finally, UBS Group lifted their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Pediatrix Medical Group has an average rating of "Hold" and an average target price of $16.42.

Pediatrix Medical Group Stock Performance

Shares of MD stock traded up $0.39 during trading hours on Monday, hitting $14.46. The stock had a trading volume of 865,072 shares, compared to its average volume of 851,380. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The firm has a market capitalization of $1.24 billion, a PE ratio of -4.60, a PEG ratio of 2.00 and a beta of 1.57. The stock's 50 day moving average is $13.96 and its 200 day moving average is $10.78. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million during the quarter, compared to analysts' expectations of $498.87 million. During the same quarter in the prior year, the business earned $0.29 EPS. Pediatrix Medical Group's quarterly revenue was up .9% compared to the same quarter last year. As a group, research analysts forecast that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Pediatrix Medical Group news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark S. Ordan sold 27,600 shares of the business's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now directly owns 138,683 shares of the company's stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Institutional Trading of Pediatrix Medical Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth about $31,000. Innealta Capital LLC acquired a new stake in Pediatrix Medical Group during the second quarter worth approximately $33,000. Quest Partners LLC grew its stake in Pediatrix Medical Group by 25.6% in the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company's stock worth $35,000 after acquiring an additional 622 shares during the period. Nisa Investment Advisors LLC raised its holdings in Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock valued at $36,000 after acquiring an additional 1,524 shares during the last quarter. Finally, Quarry LP lifted its stake in shares of Pediatrix Medical Group by 54.1% during the 3rd quarter. Quarry LP now owns 4,735 shares of the company's stock worth $55,000 after purchasing an additional 1,662 shares during the period. Hedge funds and other institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.